(Q48946728)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Kenji Hashimoto

series ordinal

1

1 reference

17 February 2018

http://europepmc.org/abstract/MED/21158553

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

33-36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Emerging role of glutamate in the pathophysiology of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Glutamate-based antidepressants: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Glutamatergic modulators: the future of treating mood disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Increased levels of glutamate in brains from patients with mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Translational control of long-lasting synaptic plasticity and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

mTOR signaling: at the crossroads of plasticity, memory and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Neuroscience. A glutamate pathway to faster-acting antidepressants?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

BDNF activates mTOR to regulate GluR1 expression required for memory formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.176

21 January 2018

Identifiers

DOI

10.1586/ERN.10.176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21158553%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference